CLINICAL TRIALS PROFILE FOR TROPICAMIDE
✉ Email this page to a colleague
All Clinical Trials for tropicamide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00120432 ↗ | Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation | Completed | Khon Kaen University | Phase 3 | 2004-12-01 | The purpose of this study is to compare the efficacy on pupillary dilation between the single dose versus the three doses of 1% tropicamide with 10% phenylephrine for complete ocular examination. |
| NCT00500344 ↗ | CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography | Completed | Genentech, Inc. | Phase 1 | 2007-07-01 | CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD |
| NCT00500344 ↗ | CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography | Completed | Washington University School of Medicine | Phase 1 | 2007-07-01 | CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD |
| NCT00501878 ↗ | 2.5% and 10% Phenylephrine for Mydriasis in Diabetic Patients With Darkly Pigmented Irides | Completed | Khon Kaen University | Phase 4 | 2007-05-01 | To compare the clinical efficacy and systemic side effects between 2.5% and 10% phenylephrine for mydriasis in diabetic patient with darkly pigmented irides. |
| NCT00541177 ↗ | Study of Myopia Prevention in Children With Low Concentration of Atropine | Unknown status | Min-Sheng General Hospital | Phase 4 | 2007-04-01 | The purpose of this study is to test the hypothesis that myopia can be prevented by using a low concentration of atropine eyedrops once a week. |
| NCT00642135 ↗ | CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment | Terminated | Ioltech | Phase 3 | 2006-01-01 | Pupillary dilation to perform a fundus in premature newborns and neonates is often difficult to obtain, because of the non mature iris sphincter. The fundus is essential to detect retinal anomalies (as retinopathy of prematurity or chorioretinal or disk anomalies). The aim of the study is to obtain a satisfactory degree of mydriasis with a minimal dose of two mydriatic treatments, with an optimal duration and a good tolerance of the drugs. The study will evaluate the mydriasis in premature newborns, neonates and infants justifying a mydriasis for a bilateral diagnosis fundus, using ophthalmic insert Mydriasert® versus reference treatment (association of phenylephrine and tropicamide eyedrops). Ophthalmic insert Mydriasert® can control drug dispensation and decrease the number of nurse interventions to obtain mydriasis in patients. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tropicamide
Condition Name
Clinical Trial Locations for tropicamide
Trials by Country
Clinical Trial Progress for tropicamide
Clinical Trial Phase
Clinical Trial Sponsors for tropicamide
Sponsor Name
